UniSuper Management Pty Ltd Purchases 1,530 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

UniSuper Management Pty Ltd boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 174.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,409 shares of the biopharmaceutical company’s stock after acquiring an additional 1,530 shares during the quarter. UniSuper Management Pty Ltd’s holdings in Regeneron Pharmaceuticals were worth $2,319,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Eudaimonia Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 1.2% in the 4th quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock worth $803,000 after purchasing an additional 11 shares during the period. Team Hewins LLC increased its holdings in Regeneron Pharmaceuticals by 2.5% during the first quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock valued at $434,000 after buying an additional 11 shares during the last quarter. Angeles Wealth Management LLC raised its position in Regeneron Pharmaceuticals by 3.5% in the first quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock worth $313,000 after acquiring an additional 11 shares during the period. Drive Wealth Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 4.0% during the 4th quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after acquiring an additional 12 shares during the last quarter. Finally, MCF Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 12 shares during the period. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on REGN shares. JPMorgan Chase & Co. raised their target price on Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a report on Monday, June 17th. Morgan Stanley decreased their price objective on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. TD Cowen lifted their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research report on Tuesday. Cantor Fitzgerald increased their target price on shares of Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the stock a “neutral” rating in a report on Monday. Finally, Canaccord Genuity Group restated a “buy” rating and set a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $1,074.95.

Insider Activity

In related news, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the transaction, the chief executive officer now owns 408,200 shares of the company’s stock, valued at $399,729,850. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 25,000 shares of the stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the sale, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Leonard S. Schleifer sold 22,830 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $979.23, for a total value of $22,355,820.90. Following the transaction, the chief executive officer now owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The disclosure for this sale can be found here. Insiders have sold 65,074 shares of company stock valued at $64,546,123 in the last ninety days. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded up $5.29 during trading hours on Wednesday, hitting $1,060.86. 452,574 shares of the stock traded hands, compared to its average volume of 468,089. The firm’s 50 day moving average price is $1,028.34 and its 200-day moving average price is $974.34. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The stock has a market capitalization of $116.90 billion, a price-to-earnings ratio of 31.18, a P/E/G ratio of 2.22 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a 1 year low of $721.51 and a 1 year high of $1,106.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The firm had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.19 billion. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.